Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

Congratulations to Zeinab Zammar – the 2018 recipient of the Michael Woodward/Jesse’s Journey Community Service Award

Jesse’s Journey is proud to sponsor The Michael Woodward/ Jesse’s Journey Community Service Award, given each year to a graduating student at Saunders Secondary School for exceptional achievement and outstanding service to others. This year, the award was presented to Zeinab Zammar. This young woman has shown extraordinary commitment to Saunders through her involvement in […]


PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy

SOUTH PLAINFIELD, N.J., July 9, 2018 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced the presentation of data from the Translarna (ataluren) Phase II Study 030 demonstrating that the safety and pharmacokinetic profile of Translarna in children from two to five years with nonsense mutation Duchenne muscular dystrophy (nmDMD) was consistent with that for older children.1  Importantly, the […]


Potential DMD Therapy Now in Phase 1 Trial, WVE-210201, Likely To Be Named Orphan Drug in EU

The Committee for Orphan Medicinal Products (COMP), an arm of the European Medicines Agency (EMA), is recommending that WVE-210201 be designated an orphan drug as a potential Duchenne muscular dystrophy (DMD) treatment, its developer, Wave Life Sciences, announced. WVE-210201 is an investigational compound of a type of therapy called exon skipping, which produces shorter but functional proteins. It is currently in a […]


Catabasis Pharmaceuticals Announces Plans for Edasalonexent Phase 3 POLARIS DMD Trial in Duchenne Muscular Dystrophy

CAMBRIDGE, MA, July 9, 2018 – Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced plans for the Phase 3 POLARIS DMD trial with edasalonexent in patients with Duchenne muscular dystrophy (DMD). Catabasis plans to initiate the global POLARIS DMD trial in the second half of 2018 with top-line results expected in the second […]


A note from John Davidson, June 27

20-years-ago this week I was making my way through the little villages along Highway 132 on the south shore of the St. Lawrence River. We began the week in Montmagny, about 50 kilometres east of Quebec City. This is where the salt water of the Atlantic Ocean pretty much comes to an end. There is […]


Catabasis Pharmaceuticals Presents New Edasalonexent Clinical Biomarker Data Showing NF-kB Inhibition and Target Engagement in the MoveDMD® Trial

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported new NF-kB inhibition biomarker results showing edasalonexent target engagement in the MoveDMD Phase 2 trial and open-label extension in boys affected by Duchenne muscular dystrophy (DMD). NF-kB is a fundamental driver of disease progression in DMD. These results add further support to the significant […]


Max’s Big Ride Crosses the Finish Line

The fourth annual Max’s Big Ride crossed the finish line in Ottawa on July 17, 2018. Andrew Sedmihradsky launched Max’s Big Ride in 2015, and each year since then he and his now 7-year-old son, Max, ride their cargo bike 600km from Hamilton, Ontario to Ottawa, Ontario to raise funds and awareness for Duchenne muscular […]


Early data show Sarepta’s investigational gene therapy led to robust microdystrophin expression in three DMD patients

Shares in Sarepta Therapeutics surged as much as 80 percent Tuesday after the company released preliminary data at an investor event from a Phase I/IIa trial showing that its experimental gene therapy, dubbed AAVrh74.MHCK7, boosted production of a truncated form of a muscle-making protein in three young boys with Duchenne muscular dystrophy (DMD). Specifically, the company reported that all […]


A Note from John Davidson, June 14

20-years-ago today I was in Perth-Andover, New Brunswick alongside the St. John River heading toward Quebec and province number five. Along the Trans-Canada I could hear gunfire through the trees as we passed CFB Gagetown. I just assumed the shots were coming from the practice range and that they weren’t aimed toward the highway! There […]


Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.